PREMARKET ALERT: Rigel Pharmaceuticals (RIGL)

Posted in General 
July 24th, 2009

Rigel Pharmaceutical Inc. (Nasdaq: RIGL) shares are down 24 percent to $8.75, with more than 100,000 premarket shares changing hands as of 8:15 a.m. Eastern. The company said its Phase IIb trial of its R788 candidate for treating rheumatoid arthritis did not meet efficacy endpoints in RA patients who had previously failed biologic therapies.  – Mike Tarsala

Comments are closed